

#### Events Jobs Subscribe Contact Us

Volume 3.45: November 23, 2020

#### Publications of the Week

## Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference

First Author: Kendal Jensen | Senior Author: Colin Pritchard (pictured) JAMA Oncology | UW, Brotman Baty and Fred Hutch



Researchers found that a strikingly high proportion of DNA repair gene variants in the plasma of patients with advanced prostate cancer were attributable to clonal hematopoiesis (CHIP). The CHIP variants were strongly correlated with increased age, and even higher than expected by age group. The high rate of CHIP may also have been influenced by prior exposure to chemotherapy. Profile | Abstract

⊌ f in

### A Human Cell Atlas of Fetal Chromatin Accessibility

First Author: Silvia Domcke | Senior Author: Jay Shendure (*pictured*)
Science | UW, Brotman Baty, Seattle Children's, Fred Hutch, Allen Discovery Center and Howard Hughes Medical Institute



The chromatin landscape underlying the specification of human cell types is of fundamental interest. Researchers generated human cell atlases of chromatin accessibility and gene expression in fetal tissues. For chromatin accessibility, they devised a three-level combinatorial indexing assay and applied it to 53 samples representing 15 organs, profiling ~800,000 single cells. Abstract | Press Release

### A Human Cell Atlas of Fetal Gene Expression

First Author: Junyue Cao (*pictured*) | Senior Author: Jay Shendure Science | UW, Brotman Baty, Seattle Children's, Fred Hutch, Allen Discovery Center and Howard Hughes Medical Institute



The gene expression program underlying the specification of human cell types is of fundamental interest. Researchers generated human cell atlases of gene expression and chromatin accessibility in fetal tissues. For gene expression, they applied three-level combinatorial indexing to >110 samples representing 15 organs, ultimately profiling ~4 million single cells. Abstract | Press Release

### View All Publications •

#### Local News

Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ<sup>®</sup> Assay Across its Hematology and Oncology Portfolio

UW Medicine



Commercial stage biotechnology company Adaptive Biotechnologies Corp. has announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ<sup>®</sup> Assay to assess minimal residual disease (MRD) in GSK's portfolio of hematology products. The clonoSEQ Assay is the first and only FDA-cleared assay for MRD in multiple myeloma, chronic lymphocytic and B-cell acute lymphoblastic leukemia. Read More

### Fred Hutch Begins Experimental COVID-19 Vaccine Efficacy Trial Fred Hutch

Fred Hutch is starting volunteer enrollment for a COVID-19 vaccine trial. The phase 3 study will examine whether AstraZeneca's AZD1222 vaccine can protect against COVID-19 and also prevent infection with SARS-CoV-2, the virus responsible for the COVID-19 disease. Dr. Julie McElrath (*pictured, right*), will be the principal investigator of the Fred Hutch site. **Read More** 

## Meet the 2020 Washington Research Foundation Postdoctoral Fellows Washington Research Foundation



Washington Research Foundation has announced its 2020 Postdoctoral Fellows. The fellows are funded for three years at eligible institutions in Washington state to work on ambitious projects addressing major public needs. Six of the 2020 fellows are from UW, with the remaining four from Fred Hutch.

Read More

# 'As Good as It Gets': Moderna's COVID-19 Vaccine, Which Got Its Start in Seattle, Is 94.5% Effective

GeekWire



Moderna's coronavirus vaccine trial got its start at Kaiser Permanente, with members from Seattle's tech community being part of the first group of participants to get their shots in the initial trials. The company completed enrolling 30,000 volunteers for its crucial Phase 3 trial, during which the vaccine was found to be 94.5% effective in preventing the disease. Read More

## Receptor Life Sciences Receives Research License from US DEA Receptor Life Sciences



Receptor Life Sciences has been granted a Schedule I research license from the US Drug Enforcement Agency (DEA). The license is a federal requirement for any scientific or medical personnel who intend to study, prescribe, or work with Schedule I controlled substances. "This license is an exciting milestone on our path to identifying safe and effective therapies," said Receptor CEO Greg Wesner (pictured). Read More

## Targeted Immunotherapy for Deadly Prostate Cancer Shows Promise in Preclinical Test

Preclinical Test
Fred Hutch



Scientists at Fred Hutch led by Dr. John Lee (*pictured*) have shown that some neuroendocrine prostate cancer cells have high levels of a specific protein marker, and that using this marker to guide chemotherapy to these cancer cells eradicates human tumors growing in mice. Their work was published in the journal *Clinical Cancer Research*. Read More

# Allen Institute Announces 2020 Next Generation Leaders Allen Institute for Brain Science



The Allen Institute has announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers. Now in its seventh year, the Next Generation Leaders Council advises neuroscience research efforts at the Allen Institute, namely the Allen Institute for Brain Science and the MindScope Program. Read More

## Old and Slow Isn't Always the Winning Combo for Critical Genes Fred Hutch



It's generally thought that the more critical a gene is to cellular function, the more likely it is be an "old" part of DNA and relatively unchanged by evolution. But new work from Dr. Harmit Maik (*pictured*) and scientists at Fred Hutch upend that belief by demonstrating that some essential genes are actually "young" and evolving rapidly. Read More

## View All Articles () | Submit an Article ()

## Upcoming Events in Seattle

December 1
10:00 AM

Straight Talk: Understanding the Promise of a Vaccine
Online

December 3 LabRoots: Coronavirus Virtual Event Series
6:00 AM Online

December 5 - 9 Cell Bio 2020 8:00 AM Online

December 8 The Future of Healthcare

December 10 Health Care Leadership Awards
8:00 AM Online

## View All Events 🔵 | Submit an Event 🔮

## Science Jobs in Seattle

10:00 AM

Senior Medical Scientist, Liver Disease, Pacific Northwest  $_{\mbox{\scriptsize Gilead}}$ 

Postdoctoral Research Fellow, DNA Viruses
Fred Hutch

PhD Fellow, Tuberculosis
Seattle Children's

**Regional Director, Myeloid/Hematology** Bristol Myers Squibb


Scientist, Immuno-Oncology
Systimmune

Products | Services

Bioinformatics Scientist, Immunology
Allen Institute for Immunology



Win a Framed Micrograph of the Hippocampus
Subscribe to our newsletter for a chance to win.



SUBSCRIBE NOW >

Submit your articles and events by reaching out to us at <a href="mailto:info@scienceinseattle.com">info@scienceinseattle.com</a>.

STEMCELL\*

STEMCELL Technologies STEMCELL Science N

The Stem Cell Podcast
Interviews and Updates

on Stem Cell Science

tes on Your Field

STEMCELL Science News
Free Weekly Updates on Your Field